2020—2022年第一师阿拉尔市恶性肿瘤发病分析

doi:10.11904/j.issn.1002-3070.2024.04.006

实用肿瘤学杂志 ›› 2024, Vol. 38 ›› Issue (4): 246-253.doi: 10.11904/j.issn.1002-3070.2024.04.006

2020—2022年第一师阿拉尔市恶性肿瘤发病分析

刘丽莉^1,2, 张雪云³, 张雷^4,5

1.浙江大学医学院附属邵逸夫医院新疆兵团阿拉尔医院肿瘤科(阿拉尔 843300);
2.浙江大学医学院附属邵逸夫医院肿瘤内科;
3.浙江大学医学院附属邵逸夫医院新疆兵团阿拉尔医院医保物价办;
4.浙江大学医学院附属邵逸夫医院新疆兵团阿拉尔医院耳鼻喉头颈外科;
5.浙江大学医学院附属邵逸夫医院耳鼻喉头颈外科

收稿日期:2024-03-25 修回日期:2024-08-22 出版日期:2024-08-28 发布日期:2024-09-25
通讯作者: 张雷,E-mail:dr_zhanglei@hotmail.com
作者简介:刘丽莉,女,(1984-),博士,主治医师,从事恶性肿瘤免疫治疗方面的研究。

Analysis for the incidence of malignant tumors in the first division,Alar city,from 2020 to 2022

LIU Lili^1,2, ZHANG Xueyun³, ZHANG Lei^4,5

1. Department of Oncology,Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine Alar Hospital,Alar 8300542;
2. Department of Medical Oncology,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine;
3. Medical Insurance Price Office,Sir Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine Alar Hospital;
4. Department of Otolaryngology Head and Neck Surgery,Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine Alar Hospital;
5. Department of Otolaryngology Head and Neck Surgery,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine

Received:2024-03-25 Revised:2024-08-22 Online:2024-08-28 Published:2024-09-25

摘要/Abstract

摘要： 目的分析2020—2022年第一师阿拉尔市(以下简称阿拉尔市)参保人群的恶性肿瘤发病情况,为本地区的恶性肿瘤防控工作提供参考。方法收集并整理2020—2022年阿拉尔市参保人群的恶性肿瘤发病数据,统计分性别、民族(汉族和少数民族)及年龄的恶性肿瘤粗发病率、中标发病率、世标发病率、0~74岁累积率、35~64岁截缩率、发病顺位及其构成。结果 2020—2022年阿拉尔市参保人群覆盖全市人口79.02%,新发恶性肿瘤2 778例,粗发病率为276.84/10万,中标发病率为225.64/10万,世标发病率为220.66/10万,累积率(0~74岁)为23.72%,截缩率为394.11/10万,其中女性、汉族的各项发病指标均高于男性及少数民族。40岁后发病率快速增加,60岁前女性发病率高于男性,60岁后男性高于女性。发病前5位依次为肺癌、甲状腺癌、结直肠癌、乳腺癌和胃癌,占比58.42%。男性及汉族以肺癌及消化道肿瘤为主,女性及少数民族中甲状腺癌、乳腺癌相对突出。结论阿拉尔市参保人群中,肺癌、乳腺癌、甲状腺癌和消化道恶性肿瘤是阿拉尔市参保人群中常见肿瘤,女性恶性肿瘤发病率较高。

关键词: 恶性肿瘤, 发病率, 癌谱, 阿拉尔

Abstract: Objective The Objective of this study was to analyze the incidence of malignant tumors among the insured population in the first division Alar city(hereinafter referred to as Alar city)from 2020 to 2022,and provide reference for the prevention and control of malignant tumors in the local area. Methods The data of malignant tumor incidence from the insured population in Alar city from 2020 to 2022 were collected and sorted out.The crude incidence,age-standardized incidence rate by Chinese standard population(ASIRC)and by World standard population(ASIRW),cumulative rate of 0 to 74 years old,truncated rate of 35 to 64 years old,the incidence sequence and its composition of malignant tumors were analyzed by gender,age and nationality(Han and minority). Results From 2020 to 2022,the insured population in Alar city covered 79.02% of the city′s population.There were 2,778 new malignant tumors.The crude incidence was 276.84/100,000,the ASIRC was 225.64/100,000,the ASIRW was 220.66/100,000,the cumulative rate(0-74 years old)was 23.72%,and the cutoff rate was 394.11/100,000.The incidence indicators of women and Han people were higher than those of men and ethnic minorities.The incidence increased rapidly after 40 years old,with women having higher incidence before age 60 and men having higher incidence after age 60.The top five cancers were lung cancer,thyroid cancer,colorectal cancer,breast cancer and stomach cancer,accounting for 58.42%.Lung cancer and digestive tract tumor were the main tumors in men and Han nationality,while thyroid cancer and breast cancer were relatively prominent in women and ethnic minorities. Conclusion Among the insured population in Alar city,lung cancer,breast cancer,thyroid cancer,and digestive tract cancer are the common tumors,and the incidence of malignant tumors in women is higher.

Key words: Malignant neoplasm, Incidence, Caner spectrum, Alar

中图分类号:

R73-31

刘丽莉, 张雪云, 张雷. 2020—2022年第一师阿拉尔市恶性肿瘤发病分析[J]. 实用肿瘤学杂志, 2024, 38(4): 246-253.

LIU Lili, ZHANG Xueyun, ZHANG Lei. Analysis for the incidence of malignant tumors in the first division,Alar city,from 2020 to 2022[J]. Journal of Practical Oncology, 2024, 38(4): 246-253.

参考文献

1 中国疾病预防控制中心慢性非传染性疾病预防控制中心,国家卫生健康委统计信息中心.中国死因监测数据集2021[M].北京:中国科学技术出版社,2022:27.
2 Chen W,Zheng R,Zhang S,et al.Cancer incidence and mortality in China,2013[J].Cancer Lett,2017,401:63-71.
3 Zheng R,Zhang S,Zeng H,et al.Cancer incidence and mortality in China,2016[J].JNCC,2022,2(1):1-9.
4 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
5 国务院第七次全国人口普查领导小组办公室.中国人口普查年鉴-2020上册[M].北京:中国统计出版社,2022:307.
6 Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
7 中华人民共和国国家卫生健康委员会医疗应急司.健康中国行动—癌症防治行动实施方案(2023-2030年)[J].中国肿瘤,2023,32(12):887-890.
8 Angelini M,Teglia F,Astolfi L,et al.Decrease of cancer diagnosis during COVID-19 pandemic:a systematic review and meta-analysis[J].Eur J Epidemiol,2023,38(1):31-38.
9 国家癌症中心.2020中国肿瘤登记年报[M].北京:人民卫生出版社,2021:73-74.
10 宋述铭,李改琴,赵婷,等.基于新疆恶性肿瘤现状调查提升县域肿瘤防控能力的实践[J].现代医院管理,2023,21(2):31-34.
11 龚政,申嘉丛,敬雯,等.2016年新疆生产建设兵团恶性肿瘤疾病负担研究[J].中华肿瘤防治杂志,2018,2018(22):1541-1546.
12 World health organization,the international agency for research on cancer.Age-Standardized Rate(World)per 100000,Incidence,Both sexes,in 2022[DB/OL].(2024.02.08)[2023.6.03].https://gco.iarc.fr/today/en/dataviz/bars？mode=population&group_populations=0&populations=900&sexes=0.
13 陈琼,徐慧芳,郭兰伟,等.2017年河南省恶性肿瘤发病与死亡情况分析[J].中华肿瘤防治杂志,2022,29(12):895-901.
14 孙惠昕,张茂祥,王婉莹,等.2018年黑龙江省肿瘤登记地区恶性肿瘤流行情况分析[J].肿瘤,2022,42(5):357-366.
15 Haupt S,Caramia F,Klein SL,et al.Sex disparities matter in cancer development and therapy[J].Nat Rev Cancer,2021,21(6):393-407.
16 Jackson SS,Marks MA,Katki HA,et al.Sex disparities in the incidence of 21 cancer types:quantification of the contribution of risk factors[J].Cancer,2022,128(19):3531-3540.
17 新疆生产建设兵团统计局,国家统计局兵团调查总队.新疆生产建设兵团统计年鉴—2022[M].北京:中国统计出版社,2023:53.
18 国务院第七次全国人口普查领导小组办公室.中国人口普查年鉴-2020上册[M].北京:中国统计出版社,2022:2.
19 Cao W,Chen HD,Yu YW,et al.Changing profiles of cancer burden worldwide and in China:a secondary analysis of the global cancer statistics 2020[J].Chin Med J(Engl),2021,134(7):783-791.
20 秦娜,马红霞,靳光付,等.肺癌流行病学研究年度进展2022[J].中华医学杂志,2023,103(14):1068-1073.
21 Leiter A,Veluswamy RR,Wisnivesky JP.The global burden of lung cancer:current status and future trends[J].Nat Rev Clin Oncol,2023,20(9):624-639.
22 Jemal A,Miller KD,Ma J,et al.Higher lung cancer incidence in young women than young men in the United States[J].N Engl J Med,2018,378(21):1999-2009.
23 Xia C,Dong X,Li H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants[J].Chin Med J(Engl),2022,135(5):584-590.
24 Fidler‐Benaoudia MM,Torre LA,Bray F,et al.Lung cancer incidence in young women vs.young men:a systematic analysis in 40 countries[J].Int J Cancer,2020,147(3):811-819.
25 Stapelfeld C,Dammann C,Maser E.Sex‐specificity in lung cancer risk[J].Int J Cancer,2019,146(9):2376-2382.
26 Lopiccolo J,Gusev A,Christiani DC,et al.Lung cancer in patients who have never smoked — an emerging disease[J].Nat Rev Clin Oncol,2024,21(2):121-146.
27 马晶昱,相智声,林永添,等.2011-2020年福建省肿瘤登记地区甲状腺癌流行特征及变化趋势[J].实用肿瘤学杂志,2023,37(4):301-307.
28 Yao CZ,Zhang M,Zeng YK,et al.Analysis and prediction of thyroid cancer morbidity and mortality trends in China[J].Zhonghua Liu Xing Bing Xue Za Zhi,2023,44(6):917-923.
29 Zhai M,Zhang D,Long J,et al.The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories:a systematic analysis for the Global Burden of Disease Study[J].Cancer Med,2021,10(13):4542-4554.
30 贺青卿,于芳,范子义,等.单中心2038例甲状腺癌20年随访及危险因素分析[J].中华内分泌外科杂志,2022,16(1):18-22.
31 Kim J,Gosnell JE,Roman SA.Geographic influences in the global rise of thyroid cancer[J].Nat Rev Endocrinol,2020,16(1):17-29.
32 Lu L,Mullins CS,Schafmayer C,et al.A global assessment of recent trends in gastrointestinal cancer and lifestyle-associated risk factors[J].Cancer Commun(Lond),2021,41(11):1137-1151.
33 Wu Y,Li Y,Giovannucci E.Potential impact of time trend of lifestyle risk factors on burden of major gastrointestinal cancers in China[J].Gastroenterology,2021,161(6):1830-1841.
34 Afshin A,Sur PJ,Fay KA,et al.Health effects of dietary risks in 195 countries,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].The Lancet,2019,393(10184):1958-1972.
35 第一师阿拉尔市人民政府.新疆兵团第一师阿拉尔市统计年鉴—2023[EB/OL].(2023-11-06)[2024.6.01].http://www.ale.gov.cn/ssgk/ssnj/content_97821.
36 国务院第七次全国人口普查领导小组办公室.中国人口普查年鉴-2020上册[M].北京:中国统计出版社,2022:26.
37 唐仁章,董华,刘韦淞,等.2015年海南省肿瘤登记地区不同民族恶性肿瘤发病分析[J].中华肿瘤防治杂志,2022,29(11):786-794.
38 蔡会龙,原伟光,刘思奇,等.1990年和2019年中国前列腺癌疾病负担及危险因素研究[J].临床泌尿外科杂志,2022,37(10):749-752.
39 王文光,王晨宇,兴毕,等.2010—2021年新疆地区前列腺癌患者临床特征分析[J].中国临床新医学,2022,15(9):821-831.

[1]	马娜, 刘捷. 天津市河东区2015—2020年肺癌发病与死亡情况分析[J]. 实用肿瘤学杂志, 2024, 38(4): 241-245.
[2]	殷海燕, 淳志明, 马巧君, 成涵, 丁高恒, 张海燕, 刘玉琴. 2019年甘肃省肿瘤登记地区女性乳腺癌流行特征及2010-2019年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(3): 141-148.
[3]	钟女娟, 马晶昱, 许志达. 2019年福建省福清市恶性肿瘤发病与死亡情况及2015—2019年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(1): 1-6.
[4]	韩霞, 丁高恒, 杨菁, 刘玉琴, 陈岚, 宋国贤. 2019年甘肃省肿瘤登记地区子宫体癌流行特征及2010—2019年变化趋势分析[J]. 实用肿瘤学杂志, 2024, 38(1): 7-12.
[5]	武春龙, 孙伟玲. 中国消化道肿瘤发病与死亡的年龄-时期-队列模型分析[J]. 实用肿瘤学杂志, 2023, 37(6): 459-465.
[6]	程锦, 王玮. 维甲酸诱导蛋白在消化系统恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 502-506.
[7]	赵世博, 陈永峰, 黎惠怡, 符爱珍. Agrin参与恶性肿瘤发生发展的研究现状[J]. 实用肿瘤学杂志, 2023, 37(6): 507-512.
[8]	宋述铭, 李改琴, 张黎峰, 许凯, 毛雯靖, 张光辉. 新疆医科大学附属肿瘤医院2010—2020年恶性肿瘤住院患者流行病学分析[J]. 实用肿瘤学杂志, 2023, 37(5): 389-394.
[9]	刘远霖, 冯立. miR-192-5p在恶性肿瘤中作用机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 439-442.
[10]	文洪梅, 陈杨, 石青萍, 朱云芳, 任思颖, 唐娴, 邵英, 伍福仙, 李云飞. 2018年云南省肿瘤登记地区恶性肿瘤的发病与死亡分析[J]. 实用肿瘤学杂志, 2023, 37(4): 293-300.
[11]	马晶昱, 相智声, 林永添, 温烨莹, 周衍. 2011—2020年福建省肿瘤登记地区甲状腺癌流行特征及变化趋势[J]. 实用肿瘤学杂志, 2023, 37(4): 301-307.
[12]	高哲敏, 李晓雪, 霍恺, 王立彬, 陈静, 鲁文慧. 沧州市区2010—2019年甲状腺癌发病时间趋势和生存分析[J]. 实用肿瘤学杂志, 2023, 37(3): 195-199.
[13]	杨建华, 罗赛美, 龙欣甜, 李蔚, 杨璧榕, 余龙涛, 张腾, 文洪梅. 2017年云南省肿瘤登记地区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2023, 37(1): 6-10.
[14]	马骥雄, 马菊红, 周红, 鲁朝霞, 丁高恒, 刘玉琴. 2018年甘肃省白银市恶性肿瘤发病和死亡分析[J]. 实用肿瘤学杂志, 2023, 37(1): 11-16.
[15]	王钦, 刘军杰, 陆秀鑫, 吴雅菲, 张文皓. 基于铁死亡的纳米联合疗法在恶性肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 429-434.

2020—2022年第一师阿拉尔市恶性肿瘤发病分析

Analysis for the incidence of malignant tumors in the first division,Alar city,from 2020 to 2022

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价